Dequalinium chloride hydrate
Dequalinium chloride hydrate structure
|
Common Name | Dequalinium chloride hydrate | ||
|---|---|---|---|---|
| CAS Number | 1255077-34-9 | Molecular Weight | 510.14 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C30H42ClN4O+ | Melting Point | ≥300°C (lit.) | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
| Name | Dequalinium chloride hydrate |
|---|---|
| Synonym | More Synonyms |
| Melting Point | ≥300°C (lit.) |
|---|---|
| Molecular Formula | C30H42ClN4O+ |
| Molecular Weight | 510.14 |
| InChIKey | CZCJAGQJOXJBST-UHFFFAOYSA-N |
| SMILES | Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc21.O.[Cl-].[Cl-] |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi |
| Risk Phrases | 36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | VA0700000 |
|
Design and development of novel mitochondrial targeted nanocarriers, DQAsomes for curcumin inhalation.
Mol. Pharm. 11(7) , 2334-45, (2014) Curcumin has potent antioxidant and anti-inflammatory properties but poor absorption following oral administration owing to its low aqueous solubility. Development of novel formulations to improve its... |
|
|
Antimicrobial topical agents used in the vagina.
Curr. Probl. Dermatol. 40 , 36-47, (2011) Vaginally applied antimicrobial agents are widely used in the vagina in women with lower genital tract infections. An 'antimicrobial' is a general term that refers to a group of drugs that are effecti... |
|
|
XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells.
Oncotarget , (2014) Acute myeloid leukemia (AML) is a neoplasia characterized by the rapid expansion of immature myeloid blasts in the bone marrow, and marked by poor prognosis and frequent relapse. As such, new therapeu... |
| EINECS 803-026-8 |